Resource Summary Report

Generated by NIF on Sep 17, 2026

KMS-12-PE

RRID:CVCL_1333
Type: Cell Line

Proper Citation

RRID:CVCL_1333

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1333

Proper Citation: RRID:CVCL_1333

Description: Cell line KMS-12-PE is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: PMID:2479409, PMID:2519219, PMID:2768132, PMID:9290701, PMID:9738977, PMID:10936422, PMID:11039672, PMID:15215163, PMID:16956823, PMID:17692805, PMID:18647998, PMID:20164919, PMID:20215515, PMID:21173094, PMID:25485619, PMID:25688540, PMID:25877200, PMID:26589293, PMID:28196595, PMID:30545397, PMID:32123307

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-12-PE

Synonyms: KMS 12 PE, KMS-12_PE, KMS-12PE, KMS12-PE, KMS12PE, Kawasaki Medical School-12-Pleural Effusion

Cross References: BTO:BTO_0006460, CLO:CLO_0009843, EFO:EFO_0006613, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-TABM-1088, BioSample:SAMN01821645, BioSample:SAMN01821692, BioSample:SAMN03472936, cancercelllines:CVCL_1333, Cell_Model_Passport:SIDM01035, CGH-DB:29-1, CGH-DB:9140-4, ChEMBL-Cells:CHEMBL3308553, ChEMBL-Targets:CHEMBL2366257, CLS:300286, Cosmic:753568, Cosmic:2081426, Cosmic:2367301, Cosmic:2809764,

DSMZ:ACC-606, DSMZCellDive:ACC-606, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM99383, GEO:GSM562811, GEO:GSM827273, IARC_TP53:28504, IZSLER:BS TCL 239, JCRB:JCRB0430, LINCS_LDP:LCL-2044, PharmacoDB:KMS12PE_764_2019, Progenetix:CVCL_1333, PubChem_Cell_line:CVCL_1333, Wikidata:Q54900169

ID: CVCL_1333

Record Creation Time: 20220427T220705+0000

Record Last Update: 20260913T004701+0000

Ratings and Alerts

No rating or validation information has been found for KMS-12-PE.

No alerts have been found for KMS-12-PE.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. Molecular oncology.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. bioRxiv : the preprint server for biology.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.

Yamashita Y, et al. (2020) Targeting Adaptive IRE1?? Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib. International journal of molecular sciences, 21(17).

Lee KJ, et al. (2017) Chromothripsis in Treatment Resistance in Multiple Myeloma. Genomics & informatics, 15(3), 87.